Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.
The lifelong IgG replacement therapy for patients with primary immunedeficiencies (PIDD) may be provided by intravenous (IVIG) or by subcutaneous IgG (SCIG) infusions. We investigated the impact of weekly SCIG self-infusions at home on the health-related quality of life, treatment satisfaction, and preferences in patients treated with IVIG at the hospital/doctor's office (Group A) or at home (Group B) before the study started. Forty-four adult North American PIDD patients were included in the study, 28 patients in Group A and 16 in Group B. Patients in Group A reported significantly less limitations with their work/daily activities, a significantly improved vitality, and better general health. Treatment satisfaction was significantly improved in Group A. The preference for the subcutaneous route and for home therapy was respectively 81% and 90% in Group A. In Group B, 69% preferred the subcutaneous route and 92% home therapy.
Nicolay
Uwe
U
Section of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden. uwe.nicolay@labmed.ki.se
Kiessling
Peter
P
Berger
Melvin
M
Gupta
Sudhir
S
Yel
Leman
L
Roifman
Chaim M
CM
Gardulf
Ann
A
Eichmann
Florian
F
Haag
Stefan
S
Massion
Cordula
C
Ochs
Hans D
HD
D000328:Adult; D002170:Canada; D002648:Child; D005260:Female; D018718:Home Infusion Therapy; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008137:Longitudinal Studies; D008297:Male; D017060:Patient Satisfaction; D011788:Quality of Life; D012646:Self Administration; D012680:Sensitivity and Specificity; D014481:United States
D007074:Immunoglobulin G